193 related articles for article (PubMed ID: 38243079)
1. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
[TBL] [Abstract][Full Text] [Related]
2. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
3. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
4. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
6. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
7. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
[TBL] [Abstract][Full Text] [Related]
8. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
Li C; Lanman NA; Kong Y; He D; Mao F; Farah E; Zhang Y; Liu J; Wang C; Wei Q; Liu X
J Biol Chem; 2020 Apr; 295(16):5470-5483. PubMed ID: 32184358
[TBL] [Abstract][Full Text] [Related]
10. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway.
Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y
Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600
[TBL] [Abstract][Full Text] [Related]
11. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
14. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
Wang BJ; Huang SH; Kao CL; Muller CJF; Wang YP; Chang KH; Wen HC; Yeh CC; Shih LJ; Kao YH; Huang SP; Li CY; Chuu CP
PLoS One; 2022; 17(7):e0270803. PubMed ID: 35776912
[TBL] [Abstract][Full Text] [Related]
15. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
[TBL] [Abstract][Full Text] [Related]
16. SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
Pang X; Zhang J; He X; Gu Y; Qian BZ; Xie R; Yu W; Zhang X; Li T; Shi X; Zhou Y; Cui Y
Oxid Med Cell Longev; 2021; 2021():5806602. PubMed ID: 34721759
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
[TBL] [Abstract][Full Text] [Related]
18. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.
Li Q; Deng Q; Chao HP; Liu X; Lu Y; Lin K; Liu B; Tang GW; Zhang D; Tracz A; Jeter C; Rycaj K; Calhoun-Davis T; Huang J; Rubin MA; Beltran H; Shen J; Chatta G; Puzanov I; Mohler JL; Wang J; Zhao R; Kirk J; Chen X; Tang DG
Nat Commun; 2018 Sep; 9(1):3600. PubMed ID: 30190514
[TBL] [Abstract][Full Text] [Related]
19. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract][Full Text] [Related]
20. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]